HR and breast carcinoma: Alpelisib (Piqray®, Novartis, Basel, Switzerland) is a kinase inhibitor that was developed for use in combination with endocrine therapy, specifically fulvestrant, to help overcome endocrine resistance in HR+/HER2− advanced breast cancer.